Association Between HPV Circulating Tumor DNA and Prognostic Inflammatory Indices in Oropharyngeal Squamous Cell Carcinoma: A Pilot Study

OTO Open, Год журнала: 2025, Номер 9(2)

Опубликована: Апрель 1, 2025

Abstract Circulating tumor DNA (ctDNA) has been developed as a marker of burden in human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC). Inflammatory indices are also increasingly being used prognostic surrogate markers solid tumors, including head and neck cancers. The relationship between ctDNA levels inflammatory not studied HPV‐associated OPSCC. We hypothesize that higher inflammation associated with levels. Herein, we demonstrate an association high pretreatment specific indices, which may be lower‐cost HPV act for the body's immune response to HPV‐positive

Язык: Английский

---

Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV‐Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study

Clinical Otolaryngology, Год журнала: 2025, Номер unknown

Опубликована: Апрель 22, 2025

ABSTRACT Objectives HPV‐positive oropharyngeal squamous cell carcinoma (OPSCC) and head neck of unknown primary (HNCUP) are increasing. Despite good prognosis, recurrence rates range from 10% to 25%. Surveillance with clinical controls imaging is not always reliable. Circulating tumour human papillomavirus DNA (ctHPV‐DNA) has emerged as a potential biomarker for treatment evaluation detection recurrence. We aimed investigate the correlation between ctHPV‐DNA in HPV+ OPSCC/HNCUP radiologic burden. Additionally, we sought assess whether could serve tool evaluation. Design A prospective observational cohort study. Setting This multicenter study involved three otolaryngology units located central Sweden. utilised HPV genotype‐specific assays droplet digital PCR (ddPCR) detect plasma at diagnosis follow‐up. levels were correlated radiological burden response using Kendall Rank coefficient Kruskal–Wallis test. Participants Patients undergoing definitive (chemo)radiotherapy enrolled CIRCOS Results Out 54 patients, 51 eligible analyses. At baseline, was detectable 88%. majority patients favourable according RECIST had corresponding undetectable The baseline total volume nodal ( rτ = 0.39, p < 0.01, respectively 0.26, 0.01). Conclusion shows strengthens role promising HPV‐related OPC/HNCUP. With further research on serial sampling, complement OPSCC/HNCUP. Trial Registration: NCT05904327 [ ClinicalTrials.gov ]

Язык: Английский

---

Reappraisal of p16 for Determining HPV Status of Head and Neck Carcinomas Arising in HPV Hotspots

The American Journal of Surgical Pathology, Год журнала: 2024, Номер 48(5), С. 581 - 587

Опубликована: Март 14, 2024

In an era of head and neck oncology where HPV status will soon dictate patient management, reliable detection is critical. P16 immunohistochemistry (IHC) currently recommended as the test choice for oropharyngeal squamous cell carcinomas (OPSCCs). The purpose this study was to determine performance characteristics p16 IHC based on a large clinical experience (SCC) arising from hot-spot regions neck. Consecutive OPSCCs, sinonasal SCCs, metastatic SCCs unknown primary sites were evaluated presence by PCR-based DNA testing part care. For discrepant cases, high-risk E6/E7 mRNA in situ hybridization (ISH) and, when possible, matrix-assisted laser desorption/ionization—time flight (MALDI-TOF) mass spectrometry (MassArray) genotyping performed. 746 cancers underwent PCR genotyping. There 95.6% concordance between 2 assays. Of 33 32 cases (4.3%) positive but negative. these 68% ISH, invariably related non-16 genotype. had overall accuracy 98.8%, sensitivity 99.8%, specificity 92.1%. sensitive specific assay determining status. appears vulnerable genotype diversity prone missing rare genotypes. ISH practical direct measure that may help eliminate small number false-positive avoid potential harm erroneous classification.

Язык: Английский

---

Human papillomavirus circulating tumor DNA: a diagnostic tool in squamous cell carcinoma of unknown primary—a pilot study

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Апрель 2, 2024

Introduction Neck mass is the most common presentation of human papillomavirus-related (HPV-related) oropharyngeal squamous cell carcinoma (OPSCC). Recently, circulating tumor HPV-DNA (ctHPVDNA) assays have been developed to detect active OPSCC. This pilot study investigates diagnostic accuracy ctHPVDNA in establishing HPV status for known vs. unknown OPSCC presenting as a neck mass. Methods A single-institution was conducted on all patients with between 2021 and 2022. The compared that standard procedures used obtain according American Society Clinical Oncology (ASCO) guideline primary (SCCUP). Sensitivity, specificity, positive predictive value (PPV), negative (NPV) were calculated. Results total 27 included; 70.4% current or former smokers, 48.1% (N = 13) had identifiable primaries, 51.9% 14) SCCUP. Four primaries required operative direct laryngoscopy biopsy (DLB) establish status. Two SCCUP underwent transoral robotic surgery (TORS) localize primary. Twelve therapeutic TORS dissection. gold based final histopathologic p16 situ hybridization (ISH) staining during workup/treatment. 95.8% sensitivity, 100% PPV, 75% NPV predicting HPV-positive whole sample. Binary logistic regression model using results predict significant (−2 log likelihood 5.55, χ 2 8.70, p &lt;.01, Nagelkerke’s R squared .67). Among tumors pathology, 100%. In patients, 90.9% NPV. Discussion demonstrated good both primaries. Incorporation into algorithm may reduce need multiple

Язык: Английский

---

Addressing positive multi-cancer early detection tests in head and neck Surgery: Experience with head and neck work up for high-risk referrals

Oral Oncology, Год журнала: 2024, Номер 152, С. 106809 - 106809

Опубликована: Апрель 14, 2024

Язык: Английский

---